MedTrace Logo

Autoinjector Device Assessment Study

NCT02349802 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3052

Last updated 2015-02-02

No results posted yet for this study

Summary

Phase I study to determine the device-related injection failure rate of the single-use, pre-filled autoinjector.

Conditions

  • Healthy Subjects

Interventions

DRUG

Auto-injector with exenatide suspension

A flexible study design to accommodate multiple cohorts.

DRUG

Syringe with exenatide suspension

A flexible study design to accommodate multiple cohorts.

Sponsors & Collaborators

  • Celerion

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Danielle Armas, MD · Celerion

  • Peter Davidson, DO · Celerion

  • Elise Hardy, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02349802 on ClinicalTrials.gov